Reilly Muredach P, Tall Alan R
Cardiovascular Institute, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104-6160, USA.
J Clin Invest. 2007 Mar;117(3):595-8. doi: 10.1172/JCI31608.
In this issue of the JCI, Vaisar et al. studied the proteome of HDL (see the related article beginning on page 746). They reveal, quite unexpectedly, that HDL is enriched in several proteins involved in the complement cascade, as well as in a variety of protease inhibitors, supporting the concept that HDL plays a role in innate immunity and in the regulation of proteolytic cascades involved in inflammatory and coagulation processes. The protein makeup of HDL also appears to be altered in patients with coronary artery disease. HDL proteomics is in its infancy, and preliminary findings will need to be confirmed using standardized approaches in larger clinical samples. However, this approach promises to better elucidate the relationship of HDL to atherosclerosis and its complications and could eventually help in the development of biomarkers to predict the outcome of interventions that alter HDL levels and functions.
在本期《临床研究杂志》中,维萨尔等人研究了高密度脂蛋白(HDL)的蛋白质组(见第746页开始的相关文章)。他们相当意外地发现,HDL富含几种参与补体级联反应的蛋白质以及多种蛋白酶抑制剂,这支持了HDL在先天免疫以及炎症和凝血过程中涉及的蛋白水解级联反应调节中发挥作用的概念。冠状动脉疾病患者的HDL蛋白质组成似乎也发生了改变。HDL蛋白质组学尚处于起步阶段,初步研究结果需要在更大规模的临床样本中采用标准化方法加以证实。然而,这种方法有望更好地阐明HDL与动脉粥样硬化及其并发症之间的关系,并最终有助于开发生物标志物,以预测改变HDL水平和功能的干预措施的效果。